Strata Critical Medical (SRTA) Research & Development (2020 - 2025)

Strata Critical Medical has disclosed Research & Development across 6 years of filings, most recently posting $453000.0 for Q3 2025.

• In Q3 2025, Research & Development rose 8.63% year-over-year to $453000.0; the TTM figure through Sep 2025 stood at $4.3 million (up 42.25% YoY), while the FY2024 annual figure was $3.2 million, down 31.19% from the prior year.
• Research & Development retreated to $453000.0 in Q3 2025, from $915000.0 in the prior quarter.
• Over the last five years, Research & Development for SRTA reached as high as $2.2 million in Q4 2024 and fell as low as $289000.0 in Q1 2021.
• The 5-year median for Research & Development is $879500.0 (2021), against an average of $898187.5.
• Annual changes were most pronounced in 2022 — Research & Development surged 228.79% — and 2024, when it slumped 61.25%.
• A 5-year view of Research & Development shows it stood at $844000.0 in 2021, then rose by 25.83% to $1.1 million in 2022, then fell by 6.97% to $988000.0 in 2023, then jumped by 117.91% to $2.2 million in 2024, then tumbled by 78.96% to $453000.0 in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $453000.0, $915000.0, and $812000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.